VYNE
VYNE Therapeutics Inc. NASDAQ Listed Jan 25, 2018$0.65
-0.52%
vs $0.65
Mkt Cap $27.7M
52w Low $0.29
24.4% of range
52w High $1.77
50d MA $0.66
200d MA $0.52
P/E (TTM)
—
EV/EBITDA
—
P/B
1.0x
Debt/Equity
0.0x
ROE
-95.4%
P/FCF
-0.8x
RSI (14)
46.50
ATR (14)
$0.03
Beta
1.95
50d MA
$0.66
200d MA
$0.52
Avg Volume
135.7K
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
520 U.S. Highway 22 · Bridgewater, NJ 08807 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.20 | -0.28 | -40.0% | 0.59 | +0.4% | +0.7% | +3.0% | +0.5% | -4.5% | +6.8% | — |
| Nov 6, 2025 | AMC | -0.19 | -0.17 | +10.5% | 0.35 | +1.9% | -0.3% | +3.0% | -1.3% | -1.6% | +4.8% | — |
| Aug 14, 2025 | AMC | -0.23 | -0.13 | +43.5% | 0.35 | -2.8% | +0.3% | -1.9% | -3.2% | -1.8% | -1.3% | — |
| May 8, 2025 | AMC | -0.29 | -0.20 | +31.0% | 1.30 | -2.3% | +0.0% | -3.8% | +4.8% | -3.8% | -0.8% | — |
| Mar 6, 2025 | AMC | -0.31 | -0.28 | +9.7% | 2.33 | -2.6% | -6.0% | -9.6% | -5.1% | -1.6% | +2.7% | — |
| Nov 7, 2024 | AMC | -0.24 | -0.29 | -20.8% | 3.16 | -0.3% | +0.0% | -4.4% | -0.7% | -3.0% | -2.4% | — |
| Aug 14, 2024 | AMC | -0.19 | -0.22 | -15.8% | 1.73 | +0.0% | +7.5% | +0.0% | -0.5% | -1.1% | +2.2% | — |
| May 9, 2024 | AMC | -0.24 | -0.15 | +37.5% | 2.65 | +0.8% | +0.8% | +6.0% | +2.1% | -4.5% | -2.2% | — |
| Feb 29, 2024 | AMC | -0.50 | -0.20 | +60.0% | 2.23 | -0.4% | -0.4% | +2.7% | -1.3% | +4.4% | -1.3% | — |
| Nov 13, 2023 | AMC | -0.76 | -1.85 | -143.4% | 3.48 | -2.0% | +2.6% | +15.4% | -3.4% | -1.8% | +1.0% | — |
| Aug 14, 2023 | AMC | -1.99 | -3.08 | -54.8% | 6.01 | +1.7% | -19.3% | +3.1% | -5.6% | +0.6% | -5.3% | — |
| May 11, 2023 | AMC | -2.50 | -1.74 | +30.4% | 6.10 | +10.2% | +18.5% | +6.2% | -8.2% | +1.8% | -5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 30 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.44 | $0.38 | -73.6% | -72.4% | -8.2% | -3.5% | +3.5% | -1.4% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.88 | $1.46 | -22.3% | -23.9% | +0.7% | -2.1% | -5.7% | +0.8% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.39 | $2.36 | -1.3% | -2.5% | -6.0% | -9.6% | -5.1% | -1.6% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.50 | $2.55 | +2.0% | +0.8% | +7.1% | +1.5% | +2.2% | -5.4% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.02 | $3.06 | +1.3% | -8.9% | +0.4% | -6.5% | +4.7% | +2.6% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.46 | $3.50 | +1.2% | +15.6% | +7.0% | -8.4% | -12.5% | -12.0% |
| Dec 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.50 | $2.60 | +4.0% | +2.8% | +15.6% | +8.8% | -1.9% | +0.6% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.16 | $3.15 | -0.3% | +0.0% | -4.4% | -0.7% | -3.0% | -2.4% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.85 | $1.85 | +0.0% | -3.2% | +2.8% | +2.2% | -2.7% | +1.6% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.73 | +0.0% | +7.5% | +0.0% | -0.5% | -1.1% | +2.2% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.20 | $2.19 | -0.5% | +4.5% | +2.6% | -6.4% | -21.3% | +4.6% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.41 | $2.41 | +0.0% | -1.2% | +0.0% | -5.5% | +1.3% | +0.4% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.72 | $2.77 | +1.8% | -2.6% | +0.8% | +6.0% | +2.1% | -4.5% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.62 | $2.64 | +0.8% | +3.4% | +6.6% | -5.9% | -2.6% | +0.8% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.33 | $2.33 | +0.0% | -4.3% | -0.4% | +2.7% | -1.3% | +4.4% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $3.15 | +40.3% | +23.4% | +10.1% | -2.0% | +1.7% | -0.3% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.50 | $5.50 | +0.0% | +9.3% | -19.3% | +3.1% | -5.6% | +0.6% |
| May 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.10 | $6.72 | +10.2% | +18.5% | +6.2% | -8.2% | +1.8% | -5.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.10 | $6.72 | +10.2% | +18.5% | +6.2% | -8.2% | +1.8% | -5.6% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.29 | $5.76 | -21.0% | -22.9% | -2.7% | +4.0% | +1.2% | +7.5% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.08 | $65.52 | +2.2% | +2.0% | -8.5% | +2.4% | +2.9% | -7.4% |
No insider trades available.
S-4
!!! Very High
Unknown — Merger Registration
VYNE shareholders will receive $100 cash per share in a merger, providing certainty of value and likely ending trading volatility, making this attractive for risk-averse investors seeking immediate liquidity.
Mar 31
8-K
Unknown — 8-K Filing
VYNE received a Nasdaq compliance extension for its minimum bid price, requiring a reverse stock split if needed to maintain listing—a dilutive action signaling financial distress that could further pressure shareholder value.
Mar 11
Valuation
Market Cap
$27.7M
Enterprise Value
-$1.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.03x
P/B
1.00x
P/S
61.07x
P/FCF
-0.84x
EV/EBITDA
—
Shares Out
42.8M
Financials (TTM)
Revenue
$454K
Net Income
-$21.5M
EBITDA
-$21.7M
Free Cash Flow
-$33.1M
Op Cash Flow
-$33.1M
EPS Basic
$-0.62
EPS Diluted
$-0.48
EPS Forward
$-0.59
Gross Margin
98.7%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$30.2M
Total Liab.
$2.4M
Total Equity
$27.8M
Cash
$29.0M
LT Debt
$0
Book Value/Sh
$0.65
Debt/Equity
0.00x
Current Ratio
12.53
Quick Ratio
12.53
Returns & Growth
ROE
-95.4%
ROA
-87.8%
ROIC
-107.1%
Rev Growth YoY
+13.8%
EPS Growth YoY
+34.0%
Price Returns
2W
+1.7%
1M
+7.1%
3M
+13.6%
6M
+76.9%
12M
-28.2%
Technicals
52W High
$1.77
52W Low
$0.29
50d MA
$0.66
200d MA
$0.52
RSI (14)
46.50
ATR (14)
$0.03
Beta
1.95
Avg Volume
136K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$5.75
High
$5.75
Low
$5.75
Median
$5.75
Data updated apr 27, 2026 8:35am
· Source: financialmodelingprep.com